---
title: Malignancy of Breast
markmap:
  colorFreezeLevel: 6
---

## Malignancy of Breast

### Epidemiology & Risk Factors
- Age (â†‘ with age)
- Gender (Female >> Male)
- Genetics
  - BRCA1/BRCA2 (Most common high penetrance)
  - TP53 (Li-Fraumeni)
  - PTEN (Cowden)
  - ATM, CHEK2
- Hormonal
  - Early menarche / Late menopause
  - Nulliparity / Late first full-term pregnancy
  - HRT / OC (complex relationship)
- Lifestyle
  - Obesity (post-menopausal)
  - Alcohol
  - Radiation exposure (esp. young age)
- Benign Breast Disease (Proliferative with atypia)

### Pathology
- **Types**
  - DCIS (Ductal Carcinoma In Situ)
  - LCIS (Lobular Carcinoma In Situ) - Risk marker, often bilateral
  - Invasive Ductal Carcinoma (IDC) - **Most common (70-80%)**
  - Invasive Lobular Carcinoma (ILC) - Often multicentric/bilateral, diffuse pattern
  - **Inflammatory Breast Cancer (IBC)** - Rapidly progressive, **Peau d'orange**, erythema, poor prognosis
  - **Paget's Disease of Nipple** - Eczema-like rash, associated with underlying DCIS or invasive cancer
  - Other subtypes: Medullary, Mucinous, Tubular, Papillary
- **Histologic Grade**
  - Nottingham Histologic Grade (Elston-Ellis)
  - Assesses: Tubule formation, Nuclear pleomorphism, Mitotic count
- **Receptors & Markers**
  - ER (Estrogen Receptor)
  - PR (Progesterone Receptor)
  - **HER2** (Human Epidermal growth factor Receptor 2) - **IHC / FISH**
  - Ki-67 (Proliferation index)
- **Molecular Subtypes** (Based on ER, PR, HER2, Ki-67)
  - **Luminal A** (ER+/PR+ high, HER2-, Ki-67 low) - Best prognosis, endocrine sensitive
  - Luminal B (ER+/PR+, HER2- high Ki-67 OR ER+/PR+, HER2+)
  - **HER2-enriched** (ER-/PR-, HER2+) - Targeted therapy needed
  - **Triple Negative** (ER-/PR-/HER2-) - Aggressive, chemo sensitive, basal-like

### Clinical Presentation
- Palpable Lump/Mass (Usually hard, irregular, painless)
- **Nipple Discharge** (Spontaneous, unilateral, especially **bloody** or serous)
- Skin Changes (Dimpling/retraction, **Peau d'orange**, erythema, ulceration)
- Nipple Changes (Retraction, scaling, erosion - **Paget's**)
- **Axillary Lymphadenopathy**
- Pain (usually late sign, common in benign)

### Diagnosis & Staging
- **Triple Assessment**
  1. **Clinical Examination**
  2. **Imaging**
     - **Mammography** (Screening & Diagnostic) - Findings: **Spiculated mass**, malignant calcifications (**clustered, pleomorphic**), architectural distortion
     - **Ultrasound** (Cystic vs Solid, dense breasts, axilla)
     - MRI (Problem-solving, extent of disease, high-risk screening)
  3. **Tissue Sampling**
     - FNA (Cytology only, less informative)
     - **Core Biopsy** (Histology, Receptor status) - **Standard**
     - Excisional Biopsy (Small lesions, definitive diagnosis/treatment)
- **Staging** (AJCC TNM System)
  - T: Tumor Size & Local Extension
  - N: Regional Lymph Nodes (Axillary is primary site)
  - M: Distant Metastasis (Bone, Lung, Liver, Brain)
- **Workup for Metastasis** (Stage dependent)
  - CXR, Abdominal US/CT, Bone Scan, PET-CT

### Management
- **Surgery**
  - **Breast Conserving Surgery (BCS)** - Lumpectomy + **Mandatory Radiation**
    - Contraindications: Multicentric, Large tumor size:breast ratio, Positive margins, Prior radiation, Pregnancy
  - **Mastectomy** - Usually **Modified Radical Mastectomy (MRM)** (Breast + Level I/II Axillary nodes)
- **Axillary Management**
  - **Sentinel Lymph Node Biopsy (SLNB)** - **Standard for clinically node-negative**
    - Reduces morbidity (Lymphedema) vs ALND
  - **Axillary Lymph Node Dissection (ALND)** - Indicated for clinically node-positive, or sometimes after positive SLNB (dependent on number/extent of mets - ACOSOG Z0011 criteria relevant)
- **Systemic Therapy**
  - **Neoadjuvant Therapy** (Before surgery) - Indications: **Locally advanced**, Inflammatory BC, Downstaging for BCS, HER2+ or Triple Negative (assess **pCR**)
  - **Adjuvant Therapy** (After surgery) - Reduces recurrence risk
    - **Chemotherapy** (e.g., Anthracyclines, Taxanes) - Based on stage, grade, receptors, risk profile
    - **Hormonal Therapy** (for ER/PR+)
      - **Tamoxifen** (Pre-menopausal or post-menopausal) - **SERM**
      - **Aromatase Inhibitors (AIs)** (Post-menopausal) - **Anastrozole, Letrozole, Exemestane** (Block estrogen synthesis)
    - **Targeted Therapy** (for HER2+)
      - **Trastuzumab (Herceptin)** - Monoclonal Ab
      - Pertuzumab, T-DM1
    - **CDK4/6 Inhibitors** (Palbociclib, Ribociclib, Abemaciclib) - For HR+ HER2- advanced/metastatic
- **Radiation Therapy**
  - After BCS (whole breast)
  - After Mastectomy (chest wall, regional nodes) - Based on tumor size, node #, margins
  - Palliative (bone mets)

### Follow-up & Surveillance
- Regular clinical exams, mammography
- Screening for contralateral breast cancer
- Monitoring for recurrence (Local, Regional, Distant)

### Specific Scenarios
- Pregnancy-Associated Breast Cancer (Often delayed diagnosis, advanced stage)
- Male Breast Cancer (Rare, often diagnosed late, similar management principles)

### INICET Buzzwords
- **Triple Assessment**
- **Sentinel Lymph Node Biopsy (SLNB)**
- **Modified Radical Mastectomy (MRM)**
- **Breast Conserving Surgery (BCS)**
- **DCIS vs IDC vs ILC**
- **Inflammatory Breast Cancer (IBC)**
- **Paget's Disease of Nipple**
- **ER / PR / HER2 Status**
- **Triple Negative Breast Cancer (TNBC)**
- **Luminal A/B**
- **Peau d'orange**
- **Spiculated Mass** (Malignant on mammography)
- **Malignant Microcalcifications** (Clustered, pleomorphic, casting pattern)
- **Nottingham Grade**
- **Oncotype DX / MammaPrint** (Prognostic/Predictive gene tests)
- **Tamoxifen** (SERM)
- **Aromatase Inhibitors (AIs)**
- **Trastuzumab (Herceptin)** (Anti-HER2)
- **CDK4/6 Inhibitors**
- **Neoadjuvant Therapy**
- **Pathological Complete Response (pCR)**
- **Adjuvant Therapy**
- **Axillary Lymph Node Dissection (ALND)**
- **ACOSOG Z0011** (Less ALND needed in some SLN+ cases)
- **Lymphedema** (Complication of ALND/Radiation)

